secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2023-09-21T23:59:59+00:00
Accession:  0001493152-23-033365
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos Therapeutics receives Nasdaq delisting notice; plans to appeal
--------------------------------------------------------------------

- Nasdaq determined company failed to meet $1.00 minimum bid price as of Sept 20, 2023; delisting proceedings begun.
- Also failed to meet $2.5M minimum stockholders' equity requirement as of June 30, 2023.
- Company will timely appeal and request a hearing by Sept 28, 2023; hearing stays delisting pending decision.
- Reverse stock split proposal on Sept 22 annual meeting agenda to regain bid price compliance.
- No assurance hearing panel will grant continued listing; delisting risk remains.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315223033365/0001493152-23-033365-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315223033365/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-033365

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer